Search

Displaying results 3901 - 3910 of 7059 in total
  1. Drug

    Potassium gluconate

    go.drugbank.com/drugs/DB13620
    Approved

    Potassium gluconate is a salt of [DB01345] and is classified as a food additive by the FDA [L2654]. It is also used as a potassium supplement [L2657]. Potassium is an essential nutrient. … It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function [A32222].

    Synonyms: potassium D-gluconate
  2. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. … [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144]

  3. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    to be approved by the FDA. … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism

  4. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Gantenerumab binds to a unique Aβ epitope compared to other anti-Aβ antibodies and preferentially recognizes Aβ oligomers and fibrils over monomers.[A244720] … Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary

  5. Drug

    Paroxetine

    go.drugbank.com/drugs/DB00715
    ApprovedInvestigational

    Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … [T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.

    Products: PAROXETIN 1A PHARMA 10MG, PAROXETIN 1A PHARMA 20MG
  6. Drug

    Ocrelizumab

    go.drugbank.com/drugs/DB11988
    ApprovedInvestigational

    such as a doctor's office. … [A31741] In September 2024, a formulation of ocrelizumab containing [hyaluronidase (human recombinant)] was approved by the US FDA.

  7. Drug

    Etripamil

    go.drugbank.com/drugs/DB12605
    ApprovedInvestigational

    Etripamil is a nondihydropyridine, L-type calcium channel blocker.[A275238, L54728] It is a fast-acting drug with a short duration of action. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT

  8. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors. … LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  9. Drug

    Sulfathiazole

    go.drugbank.com/drugs/DB06147
    ApprovedVet approvedWithdrawn

    Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. … Except for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.[L43942]

  10. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    [L1118] It was never approved by the FDA. … Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone.